Proceeds will advance clinical development of Nuclidium’s true theranostic pipeline and expand its global production and manufacturing network for copper-based radiopharmaceuticals
Participation is VIVES Partners’ first entry into radiopharmaceuticals space
Louvain-la-Neuve, Belgium, July 10, 2025 - VIVES Partners, the managing company of VIVES Funds, today announces its participation in an €84M ($98.8M) Series B financing for Swiss radiopharmaceuticals company Nuclidium AG. Kurma Growth Opportunities Fund, Angelini Ventures, Wellington Partners and Neva SGR (Intesa Sanpaolo Group) led the round, with DeepTech & Climate Fonds (DTCF), Bayern Kapital, Eurazeo, NRW.BANK and HighLight Capital, as well as existing investors, participating alongside VIVES Partners.
Nuclidium will use the funds to advance the clinical development of its Copper-61/Copper-67 (61Cu/67Cu) theranostic pipeline across multiple oncology indications. In parallel, the company will expand its production and manufacturing capabilities through a global production network.
This is VIVES Partners’ first participation in the radiopharmaceuticals field, a key area of interest in cancer treatment. It also marks the largest fundraising round that VIVES has participated in to date, exemplifying its strategy of expanding both the geographical scope and the stages of development at which the fund invests, including support for more mature start-ups entering clinical development.
“VIVES Partners is thrilled to be among the contributors in this significant fundraising round,” said Sandra Schoors, partner at VIVES Partners. “We have a strong belief in the potential of Nuclidium’s copper-based platform as a novel radiotheranostic. The company’s innovative approach tackles the critical limitations in current radiopharmaceutical methods, paving the way for more effective and accessible cancer treatments. We are excited to support this groundbreaking technology and look forward to its transformative impact on healthcare."
Nuclidium’s differentiated platform links tumor-targeting molecules with copper isotopes to address the current limitations in radiotheranostics, such as suboptimal clinical efficacy and complex manufacturing. The company is entering the next clinical phases with lead compounds aimed at diagnosing and treating metastatic prostate, neuroendocrine tumors and breast cancer.
About Nuclidium AG
Nuclidium AG is a clinical-stage biotechnology company pioneering the development of next-generation copper-based radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging copper isotopes – Copper-61 for diagnostics and Copper-67 for therapeutics – Nuclidium is creating a differentiated platform with the potential to overcome existing limitations in radiotheranostics. The company's operations in Switzerland and Germany combine innovative chemistry, deep clinical expertise and strategic manufacturing capabilities to deliver scalable, accessible and clinically superior theranostic solutions to patients worldwide. Nuclidium is committed to expanding the reach and efficacy of radiotheranostics, including addressing critical unmet medical needs in oncology and women’s health.
About VIVES Partners
VIVES Partners is the independent management company of VIVES II and VIVES IUF, both initiated by UCLouvain. VIVES Partners plays a pivotal role in connecting academic research and innovative projects with public and private investors. Addressing the seed funding gap, VIVES IUF serves as a catalyst for transforming academic research and start-ups into viable, high-impact ventures. Notably, portfolio companies of the VIVES II fund, the predecessor to VIVES IUF, have raised approximately €1.5 billion ($1.6bn) in financing, demonstrating VIVES Partners’ ability to transform early-stage companies from pre-seed funding into series A/B and IPOs/trade sales. VIVES Partners also holds an impressive track record in employment creation, with VIVES II contributing to the creation of 600 full-time equivalent jobs.
Media and analysts contact
Andrew Lloyd & Associates
Carol Leslie– Juliette Schmitt
carol@ala.associates – juliette@ala.associates
Tel: +44 1273 952 481